Researchers at Boston’s Mass General Brigham health system conducted a study examining whether Paxlovid could address long Covid symptoms. The trial was designed as a three-armed study that tested the full drug formulation as well as its individual component parts against a placebo, with treatment duration ranging from 15 to 25 days. Results indicated that Paxlovid did not demonstrate clinical benefit beyond placebo for individuals suffering from long Covid.
Paxlovid, a combination medication containing nirmatrelvir and ritonavir, functions by inhibiting viral replication in cases of acute Covid-19. Researchers hypothesized the drug might help long Covid patients by similarly suppressing viruses that could be persisting in their bodies following initial infection. However, this mechanism did not translate to therapeutic benefit in the study population. Co-principal investigator Lindsey Baden stated that treating viral persistence with the antiviral medication showed no evidence of clinical benefit.
The investigation, supported by funding from the National Institutes of Health, was published in the journal Lancet Infectious Diseases. The findings contrast with earlier use of Paxlovid for acute Covid-19, which typically involves a five-day treatment course. This study contributes to the ongoing medical inquiry into effective treatment options for long Covid, a condition affecting many individuals who experience persistent symptoms months after initial infection.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI